Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Kidney involvement in light-chain deposition disease].

M Merta¹, R Rysavá, J Zabka

¹I. interní klinika 1. lékarské fakulty Univerzity Karlovy a Vseobecné fakultní nemocnice, U nemocnice 2, 128 08 Praha 2, Czech Republic. merta@mbox.cesnet.cz

Sbornik Lekarsky

|April 12, 2003

Summary

Light-chain deposition disease (LCDD) involves kidney damage due to monoclonal immunoglobulin deposition. Treatment options exist, but the prognosis for LCDD patients remains serious.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of a virtual interprofessional oral-systemic health simulation experience in nursing, dentistry, medicine, and pharmacy education.

Journal of dental education·2024

Same author

The ellagic acid metabolites urolithin A and B differentially affect growth, adhesion, motility, and invasion of endometriotic cells in vitro.

Human reproduction (Oxford, England)·2021

Same author

Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury.

Journal of nephrology·2020

Same author

Acute elevation of intraocular pressure in patient with hyperlipidemic myeloma.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti·2020

Same author

Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data.

Neoplasma·2019

Same author

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.

The European journal of health economics : HEPAC : health economics in prevention and care·2019

Area of Science:

Nephrology
Hematology
Pathology

Background:

Monoclonal gammopathy (MG) can lead to various kidney involvements.
Light-chain deposition disease (LCDD) is a significant manifestation of MG, characterized by the deposition of light chains in tissues.

Observation:

Renal lesions are common, serious, and well-documented complications of LCDD.
A cohort of six patients diagnosed with LCDD via renal biopsy showed decreased renal function at diagnosis.
One patient required hemodialysis treatment.

Findings:

The pathophysiology of LCDD involves the deposition of immunoglobulin light chains or their stable domains.
Monoclonal immunoglobulin overproduction, characteristic of MG, underlies LCDD.
Clinical presentation of LCDD is multiorganic, with renal involvement being particularly prominent.

Related Experiment Videos

Implications:

Therapeutic strategies for LCDD include symptomatic management of renal failure, corticosteroids, and cytostatic therapy.
Despite treatment, the prognosis for most patients with LCDD remains guarded.
Further research into novel therapeutic approaches for LCDD is warranted to improve patient outcomes.